What is Zacks Research's Forecast for Glaukos Q2 Earnings?

Glaukos Co. (NYSE:GKOS - Free Report) - Equities researchers at Zacks Research lowered their Q2 2025 earnings estimates for Glaukos in a research note issued to investors on Wednesday, May 21st. Zacks Research analyst I. Bandyopadhyay now anticipates that the medical instruments supplier will earn ($0.28) per share for the quarter, down from their previous forecast of ($0.27). The consensus estimate for Glaukos' current full-year earnings is ($1.08) per share. Zacks Research also issued estimates for Glaukos' Q3 2025 earnings at ($0.25) EPS, Q4 2025 earnings at ($0.22) EPS, FY2025 earnings at ($0.96) EPS, Q1 2026 earnings at ($0.13) EPS, Q2 2026 earnings at $0.04 EPS, Q3 2026 earnings at $0.03 EPS, FY2026 earnings at $0.05 EPS, Q1 2027 earnings at $0.10 EPS and FY2027 earnings at $1.01 EPS.

Several other research firms have also weighed in on GKOS. Stephens cut their target price on shares of Glaukos from $140.00 to $115.00 and set an "overweight" rating on the stock in a report on Friday, May 2nd. Piper Sandler cut their target price on shares of Glaukos from $180.00 to $165.00 and set an "overweight" rating on the stock in a report on Tuesday, April 15th. Stifel Nicolaus cut their target price on shares of Glaukos from $140.00 to $115.00 and set a "buy" rating on the stock in a report on Thursday, May 1st. Morgan Stanley cut their target price on shares of Glaukos from $110.00 to $72.00 and set an "underweight" rating on the stock in a report on Tuesday, May 6th. Finally, Needham & Company LLC cut their target price on shares of Glaukos from $176.00 to $115.00 and set a "buy" rating on the stock in a report on Thursday, May 1st. One analyst has rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $134.67.

Glaukos Price Performance

Shares of GKOS stock opened at $97.38 on Friday. Glaukos has a 52-week low of $77.10 and a 52-week high of $163.71. The stock has a market cap of $5.56 billion, a PE ratio of -33.93 and a beta of 0.83. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54. The firm's 50 day moving average price is $93.51 and its two-hundred day moving average price is $124.97.

Glaukos (NYSE:GKOS - Get Free Report) last announced its quarterly earnings data on Wednesday, April 30th. The medical instruments supplier reported ($0.22) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.33) by $0.11. Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. The firm had revenue of $106.66 million for the quarter, compared to analysts' expectations of $102.78 million. During the same period last year, the firm earned ($0.70) earnings per share. The business's revenue for the quarter was up 24.6% on a year-over-year basis.

Institutional Investors Weigh In On Glaukos

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Barclays PLC grew its position in shares of Glaukos by 394.4% in the 3rd quarter. Barclays PLC now owns 89,699 shares of the medical instruments supplier's stock valued at $11,686,000 after acquiring an additional 71,556 shares during the period. SG Americas Securities LLC grew its position in shares of Glaukos by 42.1% in the 4th quarter. SG Americas Securities LLC now owns 3,641 shares of the medical instruments supplier's stock valued at $546,000 after acquiring an additional 1,078 shares during the period. Avior Wealth Management LLC bought a new position in shares of Glaukos in the 4th quarter valued at about $390,000. Zweig DiMenna Associates LLC bought a new position in shares of Glaukos in the 4th quarter valued at about $8,796,000. Finally, KBC Group NV grew its position in shares of Glaukos by 67.3% in the 4th quarter. KBC Group NV now owns 2,417 shares of the medical instruments supplier's stock valued at $362,000 after acquiring an additional 972 shares during the period. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Glaukos

In other Glaukos news, CFO Alex R. Thurman sold 1,520 shares of Glaukos stock in a transaction on Tuesday, March 25th. The shares were sold at an average price of $106.84, for a total value of $162,396.80. Following the sale, the chief financial officer now directly owns 53,431 shares in the company, valued at approximately $5,708,568.04. The trade was a 2.77% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 5.80% of the company's stock.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.